Pfizer’s Celebrex Gets Timely Boost From NIH Alzheimer’s Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
Celecoxib shows no increased cardiovascular risk in patients taking the drug for up to three years in an Alzheimer’s prevention study. NIH halts all treatment in the trial due to a naproxen safety signal and difficulty getting patients to use celecoxib following negative safety data in a colon polyp study.
You may also be interested in...
COX-2 Safety Review Will Explore Possible Mechanisms To Explain Risk
Briefing materials for advisory committee meeting suggest that FDA believes cardiovascular safety issues with Vioxx represent a class effect. Committee will be asked for views on whether COX-2s should stay on the market – after being reminded of "hope" for GI safety advantage that drove development.
COX-2 Safety Review Will Explore Possible Mechanisms To Explain Risk
Briefing materials for advisory committee meeting suggest that FDA believes cardiovascular safety issues with Vioxx represent a class effect. Committee will be asked for views on whether COX-2s should stay on the market – after being reminded of "hope" for GI safety advantage that drove development.
Pfizer's Celebrex Showed Cardiovascular Risk In 1999 Alzheimer's Study
A study of celecoxib in Alzheimer's disease patients showed a statistically significant increase in cardiovascular events versus placebo. The study data are posted on PhRMA's clinicalstudyresults.org website, but Public Citizen alleges Pfizer recently revised the posting and questions when the data were submitted to FDA.